Direct Switch from Foquest 55mg to Concerta 36mg is Not Recommended
You should not simply switch this patient from Foquest 55mg to Concerta 36mg, as this represents a significant dose reduction that will likely result in inadequate symptom control. Instead, address the dry mouth with supportive measures while maintaining therapeutic equivalence, or if switching formulations is necessary, use proper dose conversion to Concerta 54mg.
Why This Switch is Problematic
Dose Equivalence Issue
- Foquest 55mg delivers approximately 55mg of methylphenidate over the day
- Concerta 36mg delivers only 36mg of methylphenidate
- This represents a ~35% dose reduction, which will likely cause breakthrough ADHD symptoms and potential rebound effects
FDA-Approved Conversion Guidelines
According to the Concerta prescribing information, when converting from other methylphenidate formulations 1:
- Clinical judgment should guide dose selection when switching between different methylphenidate products
- The goal is to maintain therapeutic effect, not arbitrarily reduce dose
- For adults, Concerta dosing ranges from 18-72mg daily 1
Recommended Approach
Option 1: Address Dry Mouth While Maintaining Current Medication (Preferred)
Manage the adverse effect rather than compromising efficacy:
- Dry mouth is a common, manageable side effect of all methylphenidate formulations 2
- Supportive measures: sugar-free gum, frequent water sips, saliva substitutes, humidifier use
- Consider timing of medication with meals
- Assess hydration status and caffeine intake
Option 2: Switch to Equivalent Concerta Dose
If formulation change is clinically necessary:
- Switch to Concerta 54mg once daily (not 36mg) to maintain therapeutic equivalence 1
- This maintains similar total daily methylphenidate exposure
- Monitor for 2-4 weeks to assess symptom control and side effect profile
Important Caveat About Dry Mouth
Research shows that dry mouth occurs with both immediate-release and extended-release methylphenidate formulations 3:
- In one study, dry mouth was the most common adverse event with IR methylphenidate (30% of patients) 3
- Switching formulations alone may not resolve this anticholinergic side effect
- The dry mouth is likely to persist with Concerta as it's a class effect of methylphenidate
Clinical Monitoring After Any Switch
If you proceed with a formulation change:
- Assess ADHD symptom control at 1-2 weeks
- Monitor for rebound phenomena (concentration disturbances, restlessness, dysphoric mood) 4
- Check blood pressure and heart rate 2
- Evaluate treatment satisfaction and adherence 3, 5
- Be prepared to adjust dose in 18mg increments if needed 1
Key Pitfall to Avoid
Do not use adverse effects as justification for undertreating ADHD. The patient achieved symptom control on Foquest 55mg. Reducing to Concerta 36mg prioritizes side effect management over therapeutic efficacy, which contradicts evidence-based ADHD treatment principles 6, 2. Adults with untreated or undertreated ADHD experience significant functional impairment across multiple life domains 6.